Quick Answer
Harmony Biosciences Holdings, Inc. reported Long Term Debt of $143.66 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed a decrease of -11.9% in Long Term Debt from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $192.86 million | Q1 2021: $194.91 million | Q2 2021: $195.61 million | Q3 2021: $190.07 million | Q1 2022: $189.90 million | Q2 2022: $189.81 million | Q3 2022: $189.73 million | Q1 2023: $185.06 million | Q2 2023: $180.49 million | Q3 2023: $182.13 million | Q1 2024: $175.00 million | Q2 2024: $171.42 million | Q3 2024: $167.85 million | Q1 2025: $158.18 million | Q2 2025: $153.35 million | Q3 2025: $148.51 million.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Long Term Debt has grown by 46.7%.
- Historical annual values: Fiscal year 2025: $143.66 million | Fiscal year 2024: $163.02 million | Fiscal year 2023: $178.57 million | Fiscal year 2022: $189.65 million | Fiscal year 2021: $189.98 million | Fiscal year 2020: $194.25 million | Fiscal year 2019: $97.95 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: